Post by Medical Device Network

New data from LivaNova has demonstrated the clinical benefit of its programming algorithm in patients with obstructive sleep apnoea (OSA). Trial data demonstrated that the company’s PolySync programming algorithm increased the response rate for OSA patients undergoing proximal hypoglossal nerve stimulation (p-HGNS) treatment to 84.5%. Stimulation was administered via the aura6000 system, also developed by LivaNova. P-HGNS is a neuromodulation modality within aura6000 that works via a pulse generator implanted under the skin near the clavicle on the trunk of the hypoglossal nerve, which is responsible for controlling the muscles in the tongue. Meanwhile, the company’s PolySync programming algorithm is designed to expand the variety and number of possible p-HGNS stimulation fields in patients undergoing OSA treatment with aura6000. LivaNova’s chief innovation officer, Ahmet Tezel, PhD, commented: “These results underscore the strength of our underlying therapy and the opportunity to further enhance outcomes through innovation. “OSPREY demonstrated rapid and durable clinical benefit, and PolySync shows that we can meaningfully build on that foundation by improving response rates and expanding the impact of p-HGNS therapy.” #OSA #medtech #sleepapnoea #sleepmedicine Read the full report below: https://lnkd.in/ej8mnQUp